Gilgamesh Pharmaceuticals

Dalibor Sames

Professor of Chemistry at Columbia University with expertise in synthetic chemistry, medicinal chemistry, molecular design, synaptic imaging, neuropharmacology, and experimental therapeutics. Led new conceptual advances in chemical synthesis (C-H bond functionalization), developed fluorescent false neurotransmitters (FFNs), elucidated the mechanism of action of antidepressant tianeptine, expertise in iboga alkaloid and mitragynines chemistry and pharmacology.

Jonathan Sporn

MD; psychiatrist and neuroscientist; Assistant Professor of Psychiatry and Experimental Therapeutics at Columbia University; previously founded Perception Neuroscience (first exit in psychedelic space to ATAI Life Sciences).

Andrew Kruegel

Medicinal chemist, pharmacologist, and entrepreneur with 15+ years of experience designing psychoactive drugs; previously Founder & CSO of Kures Therapeutics (acquired by ATAI).